Biosimilar Newsletter Archive

61. 02.22.24 -- Analyzing & Kickstarting Organizational Quality Maturity 2/22/2024
    02/22/24 Biosimilar Development Newsletter
62. 02.15.24 -- How To Develop Innovative, Intuitive, Patient Friendly Drug Delivery Devices 2/15/2024

    02/15/24 Biosimilar Development Newsletter

63. 02.15.24 -- When Does Continuous Manufacturing Make Sense? 2/15/2024
    02/15/24 Biosimilar Development Newsletter
64. 02.08.24 -- Protein L Affinity Resin Is Ready To Move To Manufacturing 2/8/2024
    02/08/24 Biosimilar Development Newsletter
65. 02.01.24 -- A New Year's Resolution Suggestion For The FDA 2/1/2024
    02/01/24 Biosimilar Development Newsletter
66. 01.31.24 -- The Business Of Biotech: Leaders In Emerging Technologies 1/31/2024

    01/31/24 Biosimilar Development Newsletter

67. 01.28.24 -- Samsung Bioepis Releases Q124 US Biosimilars Report 1/28/2024
    01/28/24
68. 01.25.24 -- Formycon Ranibizumab Biosimilar Achieved 38% Market Share In The U.S. In Dec 2023 1/25/2024
    01/25/24 Biosimilar Development Newsletter
69. 01.18.24 -- FDA Accepts For Review BLA For A Proposed Biosimilar To Stelara 1/18/2024
    01/18/24 Biosimilar Development Newsletter
70. 01.15.24 -- Strategies To Streamline Combination Product Development For Biosimilars 1/15/2024

    01/15/24 Biosimilar Development Newsletter